What Is Percent-Free PSA? Free-to-Total PSA Ratio and Cancer Risk Assessment

01. What Is Percent-Free PSA and How Is It Calculated?

What does percent-free PSA measure?

PSA stands for prostate-specific antigen. The standard PSA blood test usually reports total PSA.

Total PSA contains clinically measurable PSA circulating in more than one molecular form.

Some PSA is attached to serum proteins. Some remains unbound.

The unbound fraction is called free PSA.

Percent-free PSA asks what proportion of the total PSA measurement is represented by that free fraction.

For example, if:

• total PSA = 6.0 ng/mL;
• free PSA = 1.2 ng/mL;

then:

Is percent-free PSA the same as the free-to-total PSA ratio?

Yes, with one small difference in how the result is expressed.

The free-to-total PSA ratio is free PSA divided by total PSA.

For example:

1.2 ÷ 6.0 = 0.20.

When that ratio is multiplied by 100, the result becomes:

20% free PSA.

The terms percent-free PSA, %fPSA and free-to-total PSA ratio therefore describe the same underlying relationship.

Why does the proportion matter more than free PSA alone?

Absolute free PSA generally changes partly with the total amount of PSA circulating.

The percentage normalizes the free fraction against the patient’s total PSA.

Consider two hypothetical patients:

Both patients have exactly the same absolute free PSA concentration.

But their percent-free PSA values are very different because their total PSA concentrations differ.

This is why the ratio—not simply the free PSA value—is generally used for cancer-risk refinement.

02. How Does Percent-Free PSA Relate to Prostate Cancer Risk?

Does a low percent-free PSA increase prostate-cancer probability?

Yes.

Across multiple studies, prostate cancer has been associated with a lower free-to-total PSA ratio than benign prostate disease.

Men with benign prostate enlargement tend, on average, to have a greater proportion of PSA circulating in the free form.

Men with prostate cancer tend, on average, to have a smaller free fraction and a larger proportion of protein-complexed PSA.

The biological distributions overlap substantially, however.

A man with BPH can have a low percentage, and a man with prostate cancer can have a relatively high percentage.

Percent-free PSA therefore changes probability; it does not determine pathology.

How are 10%, 15%, 20% and 25% free PSA commonly interpreted?

Older clinical studies created several percent-free PSA ranges that remain widely quoted.

They are most applicable to men whose total PSA falls in an intermediate range—especially approximately 4–10 ng/mL—rather than to every patient having PSA testing.

Where did the 25% percent-free PSA cutoff come from?

A landmark prospective multicenter study published in 1998 enrolled 773 men aged 50–75.

The men had:

• total PSA between 4 and 10 ng/mL;
• a prostate examination that was not suspicious for cancer;
• and a histologically confirmed benign or malignant diagnosis.

Using a percent-free PSA cutoff of 25% or lower as the threshold for biopsy detected approximately 95% of cancers while avoiding about 20% of unnecessary biopsies.

The investigators also found a continuous relationship: lower percent-free PSA was associated with progressively higher cancer probability.

Across the patient risk categories studied, estimated cancer probability ranged from approximately 8% to 56%.

Those results were clinically important, but they were generated before modern multiparametric MRI, contemporary targeted biopsy and many newer multivariable biomarkers.

They should therefore be understood as foundational evidence rather than a universal modern decision rule.

Does 25% free PSA mean the cancer risk is zero?

No.

Cancer occurred even among men with free PSA percentages above the classic 25% threshold.

Similarly, a percentage below 10% does not mean cancer is certain.

The relationship is probabilistic.

A useful way to think about it is:

• lower percentage → cancer becomes more likely;
• higher percentage → benign disease becomes relatively more likely;
• but neither direction reaches absolute certainty.

03. When Is Percent-Free PSA Useful and What Can Affect It?

When is percent-free PSA most useful?

Its classic role is in men with an intermediate total PSA where benign prostate enlargement and prostate cancer overlap substantially.

Most foundational evidence focused on total PSA between approximately 4 and 10 ng/mL.

Later studies and newer multivariable biomarker tests have expanded risk assessment into ranges such as approximately 2–10 ng/mL.

Percent-free PSA is less useful when the clinical answer is already clear from stronger information.

For example, a percentage may add relatively little when:

• the total PSA first needs to be repeated because the result may be temporary;
• there is active prostatitis or urinary infection;
• a prostate biopsy was performed recently;
• there is already a highly suspicious prostate examination;
• or MRI and other risk findings already establish a clear indication for further evaluation.

Does prostate size affect percent-free PSA?

Yes.

Research has shown that percent-free PSA tends to increase with prostate volume.

Men with larger benign glands tend to have a greater free PSA fraction.

That observation is biologically consistent with the fact that BPH and benign prostate enlargement are generally associated with more free PSA relative to total PSA than prostate cancer.

Prostate volume can be measured by ultrasound or MRI, as explained in How Is Prostate Volume Measured?

This also means percent-free PSA should not be interpreted as though prostate volume no longer matters.

Does age affect percent-free PSA?

It can.

Classic studies found that percent-free PSA tended to increase with increasing age and prostate volume.

This matters because an older man with a larger benign prostate may naturally have a different free-to-total PSA pattern from a younger man with a smaller gland.

The age effect is not large enough to turn percent-free PSA into an age-specific diagnostic test.

Age should instead remain one of several variables used when estimating cancer probability.

Can prostatitis, infection or recent procedures interfere with interpretation?

Yes.

Conditions that make total PSA temporarily unreliable can also make a derived percentage more difficult to interpret.

Examples include:

• acute prostatitis;
• febrile urinary infection;
• acute urinary retention;
• recent prostate biopsy;
• recent urinary instrumentation;
• and other circumstances that substantially disturb the patient’s usual PSA baseline.

In these settings, the first question may be whether the total PSA should be repeated after the temporary factor has resolved.

Calculating a more sophisticated ratio from a temporarily distorted PSA result does not necessarily make the underlying sample more reliable.

What happens to percent-free PSA during finasteride treatment?

Finasteride reduces both total and free PSA concentrations.

Studies in men treated for BPH found that total PSA fell by approximately 50%, while free PSA also decreased proportionally.

As a result, the free-to-total PSA ratio generally did not change significantly.

That is an important distinction.

Finasteride can make the absolute total PSA and absolute free PSA considerably lower while leaving the percentage relatively similar.

Medication history still matters because the total PSA trend itself requires treatment-aware interpretation.

04. How Does Percent-Free PSA Affect MRI and Biopsy Decisions?

Should biopsy be performed simply because percent-free PSA is below 10%?

No.

A very low percent-free PSA can substantially increase concern, particularly when total PSA is in the intermediate range.

But current prostate-cancer evaluation does not recommend a biopsy decision based on this percentage alone.

AUA guidance specifically describes percent-free PSA as one of several factors that validated risk calculators may incorporate alongside:

• total PSA;
• age;
• digital rectal examination;
• family history;
• prostate volume;
• PSA density;
• previous biopsy history;
• and other clinical information.

When the resulting probability of clinically significant prostate cancer is sufficiently low, biopsy can sometimes be deferred with appropriate future follow-up.

How does prostate MRI change the role of percent-free PSA?

Multiparametric prostate MRI provides anatomical and tissue-characteristic information that a blood biomarker cannot provide.

MRI can:

• identify suspicious prostate lesions;
• assign a PI-RADS category;
• measure prostate volume;
• allow calculation of PSA density;
• help determine whether biopsy is appropriate;
• and identify targets for biopsy when suspicious lesions are present.

Percent-free PSA provides different information.

It describes the molecular distribution of PSA circulating in blood.

The two tests are therefore complementary rather than interchangeable.

A reassuring percent-free PSA does not erase a highly suspicious MRI lesion, and a low percentage does not automatically require biopsy when the combined clinical and MRI risk remains low.

Are newer biomarker tests more informative than percent-free PSA alone?

Some are.

Current EAU guidance describes several multivariable blood tests that incorporate free PSA or related PSA forms.

The Prostate Health Index (PHI) combines:

• total PSA;
• free PSA;
• and the [-2]proPSA isoform.

The 4Kscore combines:

• total PSA;
• free PSA;
• intact PSA;
• human kallikrein 2;
• and selected clinical factors.

EAU evidence reports that PHI and the 4Kscore outperform the free-to-total PSA ratio alone for prediction of clinically significant prostate cancer among men with PSA approximately 2–10 ng/mL.

Other validated risk models may incorporate percent-free PSA together with age, examination and additional laboratory information.

This does not make percent-free PSA obsolete.

It means the ratio is increasingly one component of a broader risk-assessment system.

How is percent-free PSA different from PSA density?

The two measurements refine PSA in completely different ways.

Percent-free PSA examines the molecular form of PSA:

How much of total PSA is circulating unbound?

PSA density examines PSA in relation to prostate anatomy:

How much total PSA is present relative to the volume of the prostate?

Both can help refine prostate-cancer probability, but neither is a cancer diagnosis.

The next guide explains PSA Density, including how prostate volume changes the interpretation of the same total PSA result.